遺伝性乳がんと卵巣がん症候群治療の世界市場レポート 2024年

遺伝性乳がんと卵巣がん症候群治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.3%の年間複合成長率（CAGR）で85億7,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、人工知能の役割の増大、遺伝カウンセリングへの幅広いアクセス、標的療法に対する規制当局の承認、個別化された治療計画の開発、調査における国際協力に起因すると考えられます。予測期間の主要動向には、遺伝子編集技術の使用、免疫療法の進歩、腫瘍学の技術進歩、BRCA関連がんに対する免疫療法の適用、包括的な集学的ケアアプローチの導入が含まれます。

遺伝性疾患の予想される増加は、今後数年間で遺伝性乳がんと卵巣がん症候群治療市場の成長を促進すると予想されます。乳児の特定の健康状態を調べる出生後の検査である新生児スクリーニングにより、医療専門家は潜在的な健康上の問題が発生する前に特定のニーズを特定し、対処することができます。このスクリーニングにより、乳がんや卵巣がんを発症するリスクが高い乳児を特定でき、早期の予防策が可能になります。 2022年にテキサス州保健局は、新生児スクリーニング検体を受け取った人数が4.3%増加し、2021年の72万9,347人から2022年には76万1,000人に増加したと報告しました。このうち、約39万4,000人の乳児がスクリーニングを受け、そのうち1,130人がNBS疾患のいずれかに罹患していました。したがって、遺伝性疾患の急増は、遺伝性乳がんと卵巣がん症候群治療市場の成長を推進する重要な要因です。

卵巣がんの有病率の上昇により、遺伝性乳がんと卵巣がん症候群治療市場の成長がさらに促進されると予想されます。卵巣の悪性腫瘍である卵巣がんは、長寿化、出産の遅れ、ライフスタイルの変化などの要因により罹患率が増加しています。乳がん、卵巣がん、その他のがんのリスクを高める遺伝性疾患である遺伝性乳がん卵巣がん症候群（HBOC）が、この傾向に大きく貢献しています。世界卵巣がん連合の2022年 2月の報告書によると、2020年には世界で31万3,959人の女性が卵巣がんに罹患し、この数は2020年から2040年の間に42%増加して44万5,721人になると予測されています。その結果、卵巣がんの有病率の増加が原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の遺伝性乳がんと卵巣がん治療症候群市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の遺伝性乳がんと卵巣がん症候群治療市場規模実績と成長、2018～2023年
• 世界の遺伝性乳がんと卵巣がん治療症候群の市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の遺伝性乳がんと卵巣がん症候群治療市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• ホルモン療法
• 化学予防
• 遺伝カウンセリング
• 薬物療法
• その他
• 世界の遺伝性乳がんと卵巣がん治療症候群市場、診断別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 遺伝子検査
• 磁気共鳴画像法（MRI）
• マンモグラフィー
• その他
• 世界の遺伝性乳がんと卵巣がん治療症候群市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 経口
• 非経口
• その他
• 世界の遺伝性乳がんと卵巣がん治療症候群市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• 専門クリニック
• 在宅医療
• その他

第7章 地域と国の分析

• 世界の遺伝性乳がんと卵巣がん治療症候群治療市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の遺伝性乳がんと卵巣がん治療症候群治療市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝性乳がんと卵巣がん症候群治療市場の競合情勢
• 遺伝性乳がんと卵巣がん症候群治療市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Private Limited
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co.
  • AbbVie Inc.

第31章 その他の大手と革新的な企業

• Bayer AG
• Sanofi-Aventis LLC
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Co. Ltd.
• Vertex Pharmaceuticals Inc.
• Mercy Health
• Hikma Pharmaceuticals plc
• Amneal Pharmaceuticals LLC
• Lupin Limited
• Seagen Inc.
• LEO Pharma Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Treatment for hereditary breast and ovarian cancer syndrome (HBO) refers to a comprehensive set of measures and medical strategies aimed at addressing the heightened risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. The objective of hereditary breast and ovarian cancer syndrome (HBO) treatment is to either prevent the onset of cancer or detect it at an early, more treatable stage.

The primary treatments for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counseling, medication, and other therapeutic approaches. Hormone replacement therapy, specifically estrogen-based and of a temporary nature, is targeted at alleviating individual acute symptoms in cases of hereditary breast and ovarian cancer (HBOC) syndrome, particularly in individuals with BRCA1 or BRCA2 mutations. Diagnosis involves genetic testing, magnetic resonance imaging (MRI), mammography, and other methods. Medications can be administered through various routes, including oral, parenteral, and others, with delivery facilitated by hospitals, specialty clinics, home care services, and other healthcare providers.

The hereditary breast and ovarian cancer syndrome market research report is one of a series of new reports from The Business Research Company that provides hereditary breast and ovarian cancer syndrome market statistics, including hereditary breast and ovarian cancer syndrome industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome market share, detailed hereditary breast and ovarian cancer syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome industry. This hereditary breast and ovarian cancer syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.28 billion in 2023 to $6.72 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The expansion observed in the historical period can be attributed to factors such as heightened awareness and screening practices, supportive government policies, initiatives promoting patient advocacy and empowerment, and collaborative efforts in research.

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $8.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period can be attributed to the increasing role of artificial intelligence, broader access to genetic counseling, regulatory approvals for targeted therapies, the development of personalized treatment plans, and international collaborations in research. Key trends in the forecast period encompass the use of gene editing technologies, advancements in immunotherapy, technological progress in oncology, the application of immunotherapy for BRCA-related cancers, and the adoption of comprehensive multidisciplinary care approaches.

The anticipated increase in genetic disorders is set to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Newborn screening, a post-birth examination for specific health conditions in infants, enables health professionals to identify and address specific needs before any potential health issues arise. This screening could identify infants at a higher risk of developing breast and ovarian cancer, allowing for early preventive measures. In 2022, the Texas Department of State Health Services reported a 4.3% increase in newborn screening specimens received, rising from 729,347 in 2021 to 761,000 in 2022. Of these, approximately 394,000 babies were screened, with 1,130 affected by one of the NBS disorders in 2022. Therefore, the surge in genetic disorders is a key factor propelling the growth of the hereditary breast and ovarian cancer syndrome treatment market.

The rising prevalence of ovarian cancer is expected to further fuel the growth of the hereditary breast and ovarian cancer syndrome treatment market. Ovarian cancer, a malignant tumor in the ovaries, has seen increased prevalence due to factors such as increased longevity, delayed childbearing, and changes in lifestyle. Hereditary Breast and Ovarian Cancer Syndrome (HBOC), a genetic condition elevating the risk of breast, ovarian, and other cancers, is a significant contributor to this trend. According to the World Ovarian Cancer Coalition's February 2022 report, ovarian cancer affected 313,959 women globally in 2020, and this number is projected to rise by 42% to 445,721 between 2020 and 2040. Consequently, the growing prevalence of ovarian cancer is a driving force behind the growth of the hereditary breast and ovarian cancer syndrome treatment market.

The presence of alternative treatment options is expected to pose a challenge to the future expansion of the hereditary breast and ovarian cancer syndrome treatment market. The availability of alternative treatments may lead to price competition, as patients might opt for perceived safer or more effective alternatives. Notably, the cost of genetic testing for BRCA mutations has significantly decreased in recent years, potentially impacting market profitability. Therefore, the existence of alternative treatment options is likely to impede the growth of the hereditary breast and ovarian cancer syndrome treatment market.

Major companies in the hereditary breast and ovarian cancer syndrome treatment market are adopting innovative treatment options, such as comprehensive risk tests, to enhance their services. A comprehensive risk assessment test is a tool designed to identify an individual's risk of developing a disorder or experiencing symptoms of a disease. Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a groundbreaking comprehensive risk assessment test in February 2023. This test combines gene mutation testing for breast and ovarian cancers, assesses hereditary and non-hereditary risk factors, and calculates the GeneType risk score for both cancers. It targets women over 30 at a higher risk of breast and ovarian cancer in the general population.

In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation to streamline the genetic testing process. This collaboration aims to integrate genetic information into standard workflows, facilitating enhanced personalized healthcare delivery within the Epic community. Epic Systems Corporation, a US-based platform provider, plays a crucial role in evaluating a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC , AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited , Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary breast and ovarian cancer syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary breast and ovarian cancer syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary breast and ovarian cancer syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Treatment: Hormonal Therapy; Chemoprevention; Genetic Counselling; Medication; Other Treatments
• 2) By Diagnosis: Genetic Testing; Magnetic Resonance Imaging (MRI); Mammography; Other Diagnosis
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Characteristics

3. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Trends And Strategies

4. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size and Growth

• 5.1. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Segmentation

• 6.1. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hormonal Therapy
• Chemoprevention
• Genetic Counselling
• Medication
• Other Treatments
• 6.2. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Genetic Testing
• Magnetic Resonance Imaging (MRI)
• Mammography
• Other Diagnosis
• 6.3. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users

7. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 8.1. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 9.1. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 9.2. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 10.1. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 11.1. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 11.2. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 12.1. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 13.1. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 14.1. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 14.2. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 15.1. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 15.2. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 16.1. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 17.1. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 18.5. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 19.9. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 20.13. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 21.1. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 21.2. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 22.1. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 23.1. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 23.2. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 24.1. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 24.2. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 25.1. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 25.2. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 26.1. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 26.2. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 27.1. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 28.1. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 28.2. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 29.1. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 29.2. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Landscape
• 30.2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Private Limited
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi-Aventis LLC
• 31.3. AstraZeneca plc
• 31.4. Abbott Laboratories
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Co. Ltd.
• 31.9. Vertex Pharmaceuticals Inc.
• 31.10. Mercy Health
• 31.11. Hikma Pharmaceuticals plc
• 31.12. Amneal Pharmaceuticals LLC
• 31.13. Lupin Limited
• 31.14. Seagen Inc.
• 31.15. LEO Pharma Inc.

32. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Benchmarking

33. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

35. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Future Outlook and Potential Analysis

• 35.1 Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer